Michael D. Taylor, Ph.D. – President and Chief Executive Officer
Mike joined Ensemble Therapeutics as President and CEO in July of 2007 with more
than 20 years experience in the pharmaceutical industry. Prior to joining Ensemble, Mike
was Senior Vice President for Pfizer’s Global R&D division responsible
for global project and portfolio management. In other positions with
Pfizer (and previously Warner-Lambert/Parke-Davis), Mike led early and late-stage
development projects across multiple therapeutic areas, including Lipitor® and
Neurontin®. His career includes extensive experience in drug discovery,
licensing and business development, and managing R&D alliances with pharmaceutical
and biotech partners. In addition to his R&D experience he is active
in investor development, government affairs and public policy affecting the
pharmaceutical industry. Until 2003 he was Adjunct Professor of Medicinal Chemistry
at the College of Pharmacy at the University of Michigan, where he was active
in teaching medicinal chemistry and biopharmaceutics. Mike has authored or
coauthored 65 manuscripts and published abstracts and holds 6 patents.
Mike holds a Ph.D. in Medicinal Chemistry from the State University
of New York at Buffalo and was awarded an NIH postdoctoral fellowship
in natural products synthesis and structure elucidation at the University
Nick K. Terrett, Ph.D. - Chief Scientific Officer
Nick joined Ensemble Therapeutics as the Chief Scientific Officer in May
of 2006. In his role as CSO, Nick heads up our drug discovery program
investigating the rapid synthesis of macrocycles using DNA-Programmed
Chemistry, as drug candidates for disease relevant protein-protein
and protease targets.
After working as a medicinal chemist for Glaxo, Nick joined Pfizer in
Sandwich, England in 1984. He worked initially in cardiovascular disease,
and is an inventor on patents for the neutral endopeptidase inhibitor
candoxatrilat. Later he led the chemistry team on cGMP PDE inhibitors
for angina and erectile dysfunction, and is an inventor on patents for
Viagra®. Subsequently, Nick established Pfizer’s combinatorial
chemistry group and authored several related papers and a textbook. He
also managed the high throughput screening group and materials management,
and played a key role in the global integration of the Pfizer, Warner-Lambert
and Pharmacia compound collections. In 2003 Nick moved to the Pfizer
Research Technology Center in Cambridge, Massachusetts, to lead the Chemical
Sciences group investigating new targets for drug discovery and new chemistry
Nick has a B.A. and Ph.D. in
Natural Sciences from Cambridge University.
David J. Livingston, Ph.D. - Senior Vice President, Biology
David joined Ensemble Therapeutics in 2007 as Senior Vice President, Biology,
with 20 years of experience in drug discovery research and development.
He is also an Adjunct Associate Professor at Brown University in the
Department of Molecular Pharmacology, Physiology and Biotechnology.
Prior to joining Ensemble, David was President of Biomedical Strategies
Consulting, where he advised biotechnology clients on new therapeutic
targets and technologies for drug development. Prior to consulting,
David was President and CEO of Spherics, Inc., a drug delivery company,
and of Praelux Inc. (now part of G.E. Healthcare), which invented a
rapid confocal imaging platform for high-content cell-based assays
for drug discovery. David also spent three years at Integrated
Genetics, and nine years at Vertex Pharmaceuticals, where he was Vice
President and Program Executive for the company’s inflammation
program. He is an inventor on more than 20 US patents.
David holds a Ph.D. from the University of California at Davis, an MBA
from Northeastern University in Boston, and a B.S. from the University
of Massachusetts at Amherst. He was an NIH Postdoctoral Fellow at the
Massachusetts Institute of Technology and at The Johns Hopkins University
Ted Hibben - Senior Vice President, Corporate Development
Ted joined Ensemble Therapeutics in September 2010 as Senior Vice President, Corporate Development. He brings to Ensemble nearly 20 years of biotech experience in business and corporate development and strategy, venture fundraising, M&A and on leadership teams associated with a variety of early-to-mid development stage therapeutic technology platforms addressing inflammation, cancer, autoimmune and infectious diseases. Ted came to Ensemble from Cequent Pharmaceuticals, a company developing therapeutics based on RNAi, where he was Chief Business Officer and played a key role in effecting Cequent’s $46 million merger with MDRNA, Inc. (now Marina Biotech). Prior to Cequent, he was Vice President, Business Development and Alliance Management at Coley Pharmaceutical Group where he sourced and/or managed nine development collaborations and led the process to sell Coley to Pfizer for $233 million in 2008. Earlier, Ted was integral to advancing Centagenetix’s merger with Elixir, Ontogeny’s merger with Creative BioMolecules to form Curis, and Marathon Biopharmaceutical’s acquisition by Ligand.
Ted earned his M.B.A. from Harvard University and his A.B. from Dartmouth College.
Stephen P. Hale, Ph.D. - Vice President, Screening & Biochemistry
Stephen joined Ensemble Therapeutics in 2006 as Senior Director, Biology. Prior to Ensemble, Dr. Hale was at Praecis Pharmaceuticals for four years as Senior Director of Lead Discovery responsible for all biological aspects of the preclinical drug discovery program. He was a key inventor, leader in the implementation, and involved in business development of the Direct Select drug discovery platform. The value of the platform subsequently led to the acquisition of Praecis by GlaxoSmithKline plc. In his prior experience, he was a founding scientist at Phylos Inc. and held positions of increasing responsibility in both the microarray and therapeutic areas over his 5 year tenure. At Phylos Inc., Dr. Hale was a leader in the development of diagnostic protein arrays and the concurrent development of a preclinical pipeline of protein therapeutics, namely antibodies and antibody-mimic molecules. He led the team at Phylos Inc. responsible for the identification of a human fibronectin-based VEGF/KDR antagonist that was acquired by Adnexus Therapeutics Inc. and is currently in clinical trials. Dr. Hale was also a consultant to Cubist Pharmaceuticals and involved in early work at Genex Inc. on the design and engineering of single-chain antibodies as commercial alternatives to full-length antibodies.
He received his Ph.D in biochemistry from the University of Maryland, College Park, and was a National Institutes of Health post-doctoral fellow at the Massachusetts Institute of Technology under the direction of Professor Paul Schimmel.
Andrea Szekely-Hill, CPA - Senior Director, Finance & Administration
Andrea joined Ensemble Therapeutics as Controller and has served in roles of increasing financial and operational responsibility since that time. Prior to joining Ensemble, she served as an Audit Senior Manager in the Technology, Media, and Telecommunications group at Deloitte where she worked with early stage clients in the Life Sciences and Technology industries. Prior to Deloitte, she was an Assistant Vice President at State Street Research & Management responsible for budgeting and financial reporting.
Andrea received her B.S. in Accounting from Villanova University and is a member of the American Institute of Certified Public Accountants.